 John Tentler
Concepts (390)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pyrimidines | 8 | 2020 | 472 | 1.480 |
Why?
| | Xenograft Model Antitumor Assays | 22 | 2025 | 868 | 1.340 |
Why?
| | Triple Negative Breast Neoplasms | 5 | 2020 | 202 | 1.290 |
Why?
| | Antineoplastic Agents | 19 | 2025 | 2145 | 1.290 |
Why?
| | Protein Kinase Inhibitors | 15 | 2020 | 920 | 1.280 |
Why?
| | Colorectal Neoplasms | 11 | 2018 | 799 | 1.000 |
Why?
| | Proto-Oncogene Proteins | 10 | 2018 | 646 | 0.960 |
Why?
| | Azepines | 4 | 2020 | 90 | 0.880 |
Why?
| | Piperazines | 4 | 2020 | 351 | 0.860 |
Why?
| | Quinoxalines | 2 | 2020 | 66 | 0.820 |
Why?
| | Pyrazoles | 4 | 2018 | 427 | 0.800 |
Why?
| | Melanoma | 10 | 2018 | 758 | 0.780 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2020 | 1402 | 0.760 |
Why?
| | Mice, Nude | 16 | 2020 | 696 | 0.690 |
Why?
| | Cell Proliferation | 22 | 2025 | 2482 | 0.670 |
Why?
| | beta Catenin | 2 | 2020 | 251 | 0.620 |
Why?
| | Enoyl-CoA Hydratase | 1 | 2018 | 12 | 0.610 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 210 | 0.600 |
Why?
| | Cell Line, Tumor | 25 | 2025 | 3420 | 0.560 |
Why?
| | DNA-Binding Proteins | 8 | 2015 | 1507 | 0.550 |
Why?
| | Benzimidazoles | 4 | 2013 | 169 | 0.520 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 682 | 0.510 |
Why?
| | Mutation | 11 | 2018 | 3964 | 0.480 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2018 | 383 | 0.480 |
Why?
| | Tumor Suppressor Proteins | 2 | 2015 | 328 | 0.470 |
Why?
| | Tumor Suppressor Protein p53 | 4 | 2016 | 531 | 0.460 |
Why?
| | ras Proteins | 3 | 2013 | 151 | 0.430 |
Why?
| | Pyrazines | 5 | 2013 | 92 | 0.410 |
Why?
| | Genomics | 1 | 2018 | 793 | 0.410 |
Why?
| | Apoptosis | 14 | 2025 | 2557 | 0.410 |
Why?
| | Proto-Oncogene Proteins B-raf | 4 | 2018 | 227 | 0.390 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2018 | 215 | 0.360 |
Why?
| | Drug Design | 1 | 2012 | 170 | 0.350 |
Why?
| | Mice | 22 | 2025 | 17843 | 0.350 |
Why?
| | Biomarkers, Tumor | 3 | 2017 | 1279 | 0.340 |
Why?
| | Prolactin | 7 | 2004 | 100 | 0.340 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 134 | 0.330 |
Why?
| | Histone Deacetylase Inhibitors | 3 | 2022 | 211 | 0.330 |
Why?
| | Nuclear Proteins | 1 | 2015 | 710 | 0.330 |
Why?
| | Aurora Kinase A | 4 | 2020 | 56 | 0.320 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2020 | 806 | 0.310 |
Why?
| | Animals | 45 | 2025 | 37011 | 0.290 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2013 | 328 | 0.280 |
Why?
| | Imidazoles | 4 | 2013 | 244 | 0.270 |
Why?
| | Pituitary Gland | 7 | 2003 | 149 | 0.270 |
Why?
| | Neoplasms | 4 | 2022 | 2666 | 0.270 |
Why?
| | Hydroxamic Acids | 3 | 2011 | 89 | 0.250 |
Why?
| | Ethanol | 11 | 1997 | 608 | 0.250 |
Why?
| | Gene Expression Profiling | 6 | 2018 | 1770 | 0.240 |
Why?
| | Exome | 2 | 2017 | 231 | 0.240 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2025 | 46 | 0.240 |
Why?
| | Ubiquitin-Activating Enzymes | 2 | 2016 | 17 | 0.230 |
Why?
| | Pyrimidinones | 2 | 2015 | 114 | 0.220 |
Why?
| | Transcription Factors | 4 | 2011 | 1717 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2020 | 1695 | 0.220 |
Why?
| | Breast Neoplasms | 3 | 2012 | 2249 | 0.220 |
Why?
| | Protein Biosynthesis | 2 | 2025 | 434 | 0.220 |
Why?
| | Pyridones | 2 | 2015 | 168 | 0.210 |
Why?
| | Receptor, IGF Type 1 | 3 | 2013 | 65 | 0.210 |
Why?
| | Hematologic Neoplasms | 1 | 2025 | 158 | 0.200 |
Why?
| | Cell Cycle Proteins | 3 | 2018 | 614 | 0.190 |
Why?
| | Humans | 45 | 2025 | 137514 | 0.190 |
Why?
| | Hypothalamus | 12 | 1997 | 153 | 0.190 |
Why?
| | Immunoblotting | 5 | 2015 | 307 | 0.190 |
Why?
| | Drug Synergism | 4 | 2018 | 379 | 0.180 |
Why?
| | Tumor Cells, Cultured | 3 | 2020 | 957 | 0.180 |
Why?
| | c-Mer Tyrosine Kinase | 2 | 2018 | 45 | 0.180 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 3 | 2018 | 45 | 0.170 |
Why?
| | Benzoxazoles | 1 | 2020 | 20 | 0.170 |
Why?
| | Transcription, Genetic | 4 | 2013 | 1458 | 0.170 |
Why?
| | Breast | 3 | 2018 | 153 | 0.160 |
Why?
| | Female | 27 | 2020 | 73162 | 0.160 |
Why?
| | Boronic Acids | 2 | 2011 | 38 | 0.160 |
Why?
| | Growth Hormone | 3 | 1997 | 101 | 0.160 |
Why?
| | Signal Transduction | 10 | 2018 | 5096 | 0.160 |
Why?
| | Wnt Signaling Pathway | 2 | 2019 | 193 | 0.160 |
Why?
| | eIF-2 Kinase | 1 | 2019 | 31 | 0.160 |
Why?
| | Sequence Analysis, RNA | 2 | 2018 | 451 | 0.160 |
Why?
| | Epithelial Cells | 4 | 2011 | 1099 | 0.150 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 4 | 2016 | 270 | 0.150 |
Why?
| | Phosphorylation | 6 | 2025 | 1762 | 0.150 |
Why?
| | Breast Neoplasms, Male | 1 | 2018 | 28 | 0.150 |
Why?
| | Cell Cycle | 7 | 2018 | 604 | 0.150 |
Why?
| | Linkage Disequilibrium | 1 | 2018 | 268 | 0.140 |
Why?
| | MAP Kinase Kinase Kinases | 2 | 2015 | 73 | 0.140 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2018 | 158 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 1271 | 0.140 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1060 | 0.140 |
Why?
| | Cytoskeleton | 1 | 2018 | 186 | 0.140 |
Why?
| | Genetics, Population | 1 | 2018 | 210 | 0.140 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 26 | 0.140 |
Why?
| | Somatostatin | 1 | 1997 | 62 | 0.140 |
Why?
| | Gonadotropin-Releasing Hormone | 8 | 1993 | 208 | 0.140 |
Why?
| | Armadillo Domain Proteins | 1 | 2017 | 6 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 67 | 0.130 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 53 | 0.130 |
Why?
| | Testis | 2 | 1997 | 150 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2017 | 31 | 0.130 |
Why?
| | Sexual Maturation | 1 | 1997 | 55 | 0.130 |
Why?
| | Inhibitory Concentration 50 | 2 | 2016 | 90 | 0.130 |
Why?
| | Cyclopentanes | 1 | 2016 | 20 | 0.130 |
Why?
| | Adenine | 1 | 2018 | 268 | 0.130 |
Why?
| | Mucous Membrane | 1 | 2017 | 125 | 0.130 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 1997 | 145 | 0.130 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 1997 | 136 | 0.130 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 17 | 0.130 |
Why?
| | Gene Regulatory Networks | 1 | 2018 | 308 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 765 | 0.120 |
Why?
| | Education, Graduate | 1 | 2015 | 34 | 0.120 |
Why?
| | RNA, Messenger | 10 | 2003 | 2838 | 0.120 |
Why?
| | Peptides, Cyclic | 1 | 1997 | 260 | 0.120 |
Why?
| | Drug Discovery | 1 | 2016 | 141 | 0.120 |
Why?
| | HT29 Cells | 2 | 2018 | 40 | 0.120 |
Why?
| | Tumor Protein p73 | 1 | 2015 | 14 | 0.120 |
Why?
| | Skin Neoplasms | 2 | 2013 | 853 | 0.120 |
Why?
| | Neoplasm Invasiveness | 3 | 2018 | 510 | 0.120 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2013 | 156 | 0.110 |
Why?
| | Phosphoproteins | 1 | 2017 | 338 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2014 | 316 | 0.110 |
Why?
| | Luteinizing Hormone | 8 | 1993 | 185 | 0.110 |
Why?
| | Computational Biology | 2 | 2016 | 645 | 0.110 |
Why?
| | Cluster Analysis | 2 | 2012 | 502 | 0.110 |
Why?
| | Testosterone | 2 | 1997 | 399 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2018 | 3546 | 0.110 |
Why?
| | Protein Kinases | 1 | 2015 | 319 | 0.110 |
Why?
| | Genotype | 1 | 2018 | 1920 | 0.100 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2017 | 434 | 0.100 |
Why?
| | Receptor, Insulin | 1 | 2013 | 105 | 0.100 |
Why?
| | Ubiquitin-Conjugating Enzymes | 1 | 2013 | 13 | 0.100 |
Why?
| | Phenotype | 3 | 2018 | 3205 | 0.100 |
Why?
| | Cell Survival | 4 | 2019 | 1122 | 0.100 |
Why?
| | Tumor Stem Cell Assay | 1 | 2012 | 34 | 0.100 |
Why?
| | Aurora Kinases | 1 | 2012 | 27 | 0.100 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 69 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-ets | 4 | 2011 | 56 | 0.100 |
Why?
| | BRCA1 Protein | 1 | 2013 | 76 | 0.100 |
Why?
| | Alcohol Oxidoreductases | 1 | 2013 | 62 | 0.100 |
Why?
| | Rats | 21 | 2004 | 5676 | 0.100 |
Why?
| | Genes, p53 | 1 | 2012 | 72 | 0.100 |
Why?
| | Mitochondria | 1 | 2018 | 947 | 0.090 |
Why?
| | Cyclosporine | 1 | 2013 | 268 | 0.090 |
Why?
| | Positron-Emission Tomography | 2 | 2011 | 299 | 0.090 |
Why?
| | MicroRNAs | 1 | 2018 | 704 | 0.090 |
Why?
| | Receptor, ErbB-2 | 2 | 2012 | 342 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2012 | 75 | 0.090 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 414 | 0.090 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2013 | 179 | 0.090 |
Why?
| | Drug Screening Assays, Antitumor | 4 | 2016 | 196 | 0.090 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 45 | 0.090 |
Why?
| | Mammary Glands, Human | 1 | 2011 | 64 | 0.090 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2013 | 235 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 2193 | 0.090 |
Why?
| | Cellular Senescence | 1 | 2012 | 188 | 0.090 |
Why?
| | Transcriptional Activation | 2 | 2003 | 379 | 0.090 |
Why?
| | Cytoplasm | 1 | 2011 | 274 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 2 | 2011 | 665 | 0.090 |
Why?
| | Protease Inhibitors | 1 | 2011 | 107 | 0.080 |
Why?
| | Cell Movement | 3 | 2011 | 972 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 7 | 0.080 |
Why?
| | Ki-67 Antigen | 1 | 2010 | 112 | 0.080 |
Why?
| | Neoplasm Transplantation | 3 | 2016 | 256 | 0.080 |
Why?
| | Capillary Permeability | 1 | 2010 | 144 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 71 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2016 | 937 | 0.080 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2009 | 79 | 0.070 |
Why?
| | Cell Line | 4 | 2012 | 2852 | 0.070 |
Why?
| | Quinazolines | 1 | 2009 | 249 | 0.070 |
Why?
| | Promoter Regions, Genetic | 3 | 2004 | 1255 | 0.070 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2011 | 360 | 0.070 |
Why?
| | Peptide Fragments | 1 | 2011 | 708 | 0.070 |
Why?
| | Algorithms | 2 | 2015 | 1702 | 0.070 |
Why?
| | Pituitary Gland, Anterior | 4 | 1992 | 39 | 0.070 |
Why?
| | Enzyme Inhibitors | 3 | 2013 | 845 | 0.070 |
Why?
| | Drug Delivery Systems | 1 | 2010 | 363 | 0.070 |
Why?
| | Prognosis | 2 | 2017 | 4031 | 0.070 |
Why?
| | Colonic Neoplasms | 1 | 2009 | 258 | 0.060 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 2 | 2003 | 25 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2014 | 4295 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2010 | 3292 | 0.060 |
Why?
| | Growth Hormone-Releasing Hormone | 2 | 1997 | 24 | 0.060 |
Why?
| | Rats, Inbred Strains | 12 | 1992 | 369 | 0.060 |
Why?
| | Transplantation, Heterologous | 2 | 2016 | 195 | 0.060 |
Why?
| | Oncogene Protein p65(gag-jun) | 1 | 2004 | 2 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2004 | 55 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2025 | 141 | 0.050 |
Why?
| | Male | 25 | 2020 | 67718 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2004 | 2615 | 0.050 |
Why?
| | Transfection | 2 | 2003 | 948 | 0.050 |
Why?
| | Transcription Factor Pit-1 | 1 | 2003 | 27 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2017 | 538 | 0.050 |
Why?
| | Suppression, Genetic | 1 | 2003 | 25 | 0.050 |
Why?
| | Genes, Dominant | 1 | 2003 | 95 | 0.050 |
Why?
| | Mesoderm | 1 | 2004 | 144 | 0.050 |
Why?
| | Disease Progression | 3 | 2018 | 2755 | 0.050 |
Why?
| | Pancreatic Neoplasms | 1 | 2011 | 943 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2494 | 0.050 |
Why?
| | Histone Deacetylase 1 | 1 | 2022 | 26 | 0.050 |
Why?
| | DNA Repair | 2 | 2013 | 230 | 0.050 |
Why?
| | Caspase 3 | 2 | 2013 | 246 | 0.050 |
Why?
| | Middle Aged | 6 | 2020 | 33355 | 0.040 |
Why?
| | Blotting, Northern | 3 | 1997 | 199 | 0.040 |
Why?
| | Acetylation | 1 | 2022 | 254 | 0.040 |
Why?
| | DNA Damage | 2 | 2013 | 420 | 0.040 |
Why?
| | Aged | 5 | 2020 | 23798 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2004 | 425 | 0.040 |
Why?
| | Radioimmunoassay | 8 | 1993 | 174 | 0.040 |
Why?
| | Histone Deacetylases | 1 | 2022 | 215 | 0.040 |
Why?
| | Bortezomib | 2 | 2011 | 54 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 62 | 0.040 |
Why?
| | Maximum Tolerated Dose | 1 | 2020 | 199 | 0.040 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2019 | 40 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 125 | 0.040 |
Why?
| | Blotting, Western | 3 | 2010 | 1227 | 0.040 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2018 | 24 | 0.040 |
Why?
| | Gene Expression | 3 | 1993 | 1505 | 0.040 |
Why?
| | Azetidines | 1 | 2018 | 43 | 0.040 |
Why?
| | Spleen | 2 | 1991 | 516 | 0.040 |
Why?
| | 4-Aminobenzoic Acid | 1 | 2018 | 7 | 0.040 |
Why?
| | GTP Phosphohydrolases | 1 | 2018 | 91 | 0.040 |
Why?
| | Lymphocytes | 2 | 1991 | 395 | 0.040 |
Why?
| | Nausea | 1 | 2018 | 115 | 0.040 |
Why?
| | HCT116 Cells | 1 | 2018 | 80 | 0.040 |
Why?
| | Okadaic Acid | 1 | 1997 | 14 | 0.030 |
Why?
| | Orchiectomy | 4 | 1994 | 71 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 849 | 0.030 |
Why?
| | Colforsin | 1 | 1997 | 54 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2011 | 377 | 0.030 |
Why?
| | Diarrhea | 1 | 2018 | 183 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 3 | 1997 | 2066 | 0.030 |
Why?
| | Piperidines | 1 | 2018 | 208 | 0.030 |
Why?
| | Angiogenesis Inhibitors | 1 | 2018 | 226 | 0.030 |
Why?
| | Tumor Burden | 1 | 2018 | 311 | 0.030 |
Why?
| | Cells, Cultured | 4 | 2013 | 4206 | 0.030 |
Why?
| | Ubiquitination | 1 | 2016 | 104 | 0.030 |
Why?
| | Histones | 1 | 2022 | 641 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 329 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2004 | 1979 | 0.030 |
Why?
| | Heterografts | 1 | 2016 | 139 | 0.030 |
Why?
| | Cetuximab | 1 | 2016 | 95 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 403 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 814 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 121 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2017 | 151 | 0.030 |
Why?
| | Camptothecin | 1 | 2016 | 116 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2010 | 10821 | 0.030 |
Why?
| | Models, Educational | 1 | 2015 | 93 | 0.030 |
Why?
| | Polymerase Chain Reaction | 3 | 1993 | 1061 | 0.030 |
Why?
| | Capacity Building | 1 | 2015 | 62 | 0.030 |
Why?
| | Diphenylamine | 1 | 2014 | 9 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 185 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2016 | 401 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2017 | 7593 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1132 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2015 | 192 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2015 | 237 | 0.030 |
Why?
| | Follicle Stimulating Hormone | 2 | 1993 | 244 | 0.030 |
Why?
| | Guanine | 1 | 1994 | 79 | 0.030 |
Why?
| | Analysis of Variance | 1 | 1997 | 1324 | 0.030 |
Why?
| | Methyltransferases | 1 | 1994 | 78 | 0.030 |
Why?
| | Research Personnel | 1 | 2015 | 170 | 0.030 |
Why?
| | Gonadotropins | 1 | 1993 | 40 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 659 | 0.030 |
Why?
| | Caspase 7 | 1 | 2013 | 22 | 0.030 |
Why?
| | Benzamides | 1 | 2014 | 218 | 0.030 |
Why?
| | MAP Kinase Kinase 2 | 1 | 2013 | 28 | 0.030 |
Why?
| | Butadienes | 1 | 2013 | 37 | 0.030 |
Why?
| | Mentors | 1 | 2015 | 197 | 0.030 |
Why?
| | Program Development | 1 | 2015 | 366 | 0.030 |
Why?
| | Adult | 4 | 2018 | 37821 | 0.030 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2013 | 75 | 0.030 |
Why?
| | Kinetics | 2 | 2014 | 1679 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2013 | 98 | 0.030 |
Why?
| | Oncogene Proteins, Viral | 1 | 2013 | 23 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2011 | 2901 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 75 | 0.030 |
Why?
| | Melanocytes | 1 | 2013 | 66 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2015 | 447 | 0.020 |
Why?
| | Nitriles | 1 | 2013 | 175 | 0.020 |
Why?
| | Genes, Synthetic | 1 | 2012 | 15 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2014 | 366 | 0.020 |
Why?
| | Genes, Lethal | 1 | 2012 | 30 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2013 | 66 | 0.020 |
Why?
| | Drug Hypersensitivity | 1 | 1993 | 89 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2013 | 165 | 0.020 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 67 | 0.020 |
Why?
| | Mice, SCID | 1 | 2013 | 367 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2018 | 1167 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 426 | 0.020 |
Why?
| | Nuclear Export Signals | 1 | 2011 | 4 | 0.020 |
Why?
| | Glycoprotein Hormones, alpha Subunit | 1 | 1991 | 23 | 0.020 |
Why?
| | Nuclear Localization Signals | 1 | 2011 | 18 | 0.020 |
Why?
| | Peptide Mapping | 1 | 2011 | 64 | 0.020 |
Why?
| | Alcoholic Intoxication | 1 | 1992 | 66 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2013 | 402 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 379 | 0.020 |
Why?
| | Calcium Signaling | 1 | 2013 | 253 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2011 | 225 | 0.020 |
Why?
| | Colony-Forming Units Assay | 1 | 2010 | 91 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2011 | 309 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2010 | 111 | 0.020 |
Why?
| | Genes, ras | 1 | 2010 | 96 | 0.020 |
Why?
| | Protein Transport | 1 | 2011 | 443 | 0.020 |
Why?
| | Gene Dosage | 1 | 2010 | 148 | 0.020 |
Why?
| | Ligands | 1 | 2011 | 665 | 0.020 |
Why?
| | Drug Combinations | 1 | 2010 | 344 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2011 | 340 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2010 | 586 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2010 | 329 | 0.020 |
Why?
| | Transcriptome | 1 | 2015 | 974 | 0.020 |
Why?
| | Prolactinoma | 1 | 1989 | 13 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1293 | 0.020 |
Why?
| | Serum Albumin | 1 | 1990 | 150 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2011 | 869 | 0.020 |
Why?
| | Curriculum | 1 | 2015 | 980 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1740 | 0.020 |
Why?
| | Cell Communication | 1 | 2010 | 313 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2011 | 619 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2010 | 437 | 0.020 |
Why?
| | Pregnanediones | 1 | 1987 | 9 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 4 | 1994 | 2501 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5139 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 974 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2011 | 2146 | 0.020 |
Why?
| | Brain Chemistry | 1 | 1987 | 120 | 0.020 |
Why?
| | Sulfonamides | 1 | 2011 | 513 | 0.020 |
Why?
| | Calcium | 1 | 2013 | 1233 | 0.020 |
Why?
| | Anesthetics | 1 | 1987 | 81 | 0.020 |
Why?
| | Pituitary Neoplasms | 1 | 1989 | 190 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2010 | 950 | 0.020 |
Why?
| | Estrogens | 1 | 1989 | 361 | 0.020 |
Why?
| | Models, Biological | 1 | 2013 | 1775 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2009 | 1185 | 0.020 |
Why?
| | Metabolomics | 1 | 2011 | 679 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 1034 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 2011 | 786 | 0.010 |
Why?
| | Proto-Oncogene Protein c-ets-2 | 1 | 2004 | 4 | 0.010 |
Why?
| | Contact Inhibition | 1 | 2004 | 5 | 0.010 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2004 | 16 | 0.010 |
Why?
| | Epidermal Growth Factor | 1 | 2004 | 174 | 0.010 |
Why?
| | Antisense Elements (Genetics) | 1 | 2003 | 4 | 0.010 |
Why?
| | Collagenases | 1 | 2003 | 25 | 0.010 |
Why?
| | Matrix Metalloproteinase 3 | 1 | 2003 | 28 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2004 | 322 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2004 | 467 | 0.010 |
Why?
| | Cell Division | 1 | 2004 | 795 | 0.010 |
Why?
| | Cytokines | 1 | 2010 | 2095 | 0.010 |
Why?
| | Trans-Activators | 1 | 2004 | 399 | 0.010 |
Why?
| | HeLa Cells | 1 | 2003 | 640 | 0.010 |
Why?
| | Brain | 1 | 1992 | 2831 | 0.010 |
Why?
| | Potassium | 2 | 1990 | 151 | 0.010 |
Why?
| | Base Sequence | 2 | 1993 | 2180 | 0.010 |
Why?
| | Biological Assay | 2 | 1990 | 123 | 0.010 |
Why?
| | Hypophysectomy | 2 | 1987 | 15 | 0.010 |
Why?
| | O(6)-Methylguanine-DNA Methyltransferase | 1 | 1994 | 6 | 0.010 |
Why?
| | Cocarcinogenesis | 1 | 1994 | 14 | 0.010 |
Why?
| | Injections, Intraperitoneal | 1 | 1994 | 115 | 0.010 |
Why?
| | Rats, Mutant Strains | 1 | 1993 | 25 | 0.010 |
Why?
| | Thyrotropin | 1 | 1994 | 114 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1993 | 34 | 0.010 |
Why?
| | Adrenocorticotropic Hormone | 1 | 1994 | 142 | 0.010 |
Why?
| | Stress, Physiological | 2 | 1987 | 445 | 0.010 |
Why?
| | Blotting, Southern | 1 | 1992 | 72 | 0.010 |
Why?
| | Cyclic AMP | 1 | 1992 | 243 | 0.010 |
Why?
| | Protein Kinase C | 1 | 1992 | 265 | 0.010 |
Why?
| | Enzyme Activation | 1 | 1992 | 816 | 0.010 |
Why?
| | RNA Splicing | 1 | 1992 | 268 | 0.010 |
Why?
| | Cross Reactions | 1 | 1990 | 133 | 0.010 |
Why?
| | Dinoprostone | 1 | 1990 | 191 | 0.000 |
Why?
| | Bromocriptine | 1 | 1989 | 29 | 0.000 |
Why?
| | Norepinephrine | 1 | 1990 | 212 | 0.000 |
Why?
| | Naloxone | 1 | 1990 | 120 | 0.000 |
Why?
| | Perfusion | 1 | 1990 | 212 | 0.000 |
Why?
| | Rats, Inbred F344 | 1 | 1989 | 264 | 0.000 |
Why?
| | Depression, Chemical | 1 | 1987 | 23 | 0.000 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1990 | 595 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1990 | 1108 | 0.000 |
Why?
| | Urethane | 1 | 1987 | 43 | 0.000 |
Why?
| | Pancreas | 1 | 1990 | 328 | 0.000 |
Why?
| | Molecular Weight | 1 | 1987 | 332 | 0.000 |
Why?
| | Drug Administration Schedule | 1 | 1989 | 784 | 0.000 |
Why?
| | Dopamine | 1 | 1990 | 301 | 0.000 |
Why?
| | Ketamine | 1 | 1987 | 93 | 0.000 |
Why?
| | Cerebral Cortex | 1 | 1990 | 459 | 0.000 |
Why?
| | Restraint, Physical | 1 | 1986 | 72 | 0.000 |
Why?
| | Alcoholism | 1 | 1992 | 805 | 0.000 |
Why?
| | DNA | 1 | 1991 | 1460 | 0.000 |
Why?
| | Kidney | 1 | 1990 | 1472 | 0.000 |
Why?
| | Liver | 1 | 1990 | 1940 | 0.000 |
Why?
| | Lung | 1 | 1990 | 4066 | 0.000 |
Why?
|
|
Tentler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|